Project Grant R43CA298492
Award Date 9/10/25
Completion Date 8/31/26
Dollars Obligated $399K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to Ampedrna Biosciences LLC in the amount of $398,823 to develop a highly immunogenic mini-circular RNA (mcrRNA) therapeutic cancer vaccine for human papillomavirus (HPV)-related cancers. The goal is to create an off-the-shelf or personalized vaccine that can elicit robust and durable T cell responses to target HPV E6 and E7 antigens, which are known to drive HPV-induced cancers. The proposed...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $122,577 to Trustees of Boston University for the development and characterization of self-amplifying RNA lipid nanoparticles. The goal is to create a platform that can sustainably and simultaneously deliver multiple immunostimulatory and gene therapy payloads directly to solid tumors, which account for nearly 90% of adult cancers and are difficult to treat effectively. The project aims to...
- This federal Project Grant award of $630,781, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to develop an innovative mRNA lipid nanoparticle (LNP) vaccine platform for cancer immunotherapy. The key objectives are to: 1) Engineer mRNA LNP formulations capable of eliciting dual or biased Th1 and/or Th2 immune responses through a machine learning-aided screening process, 2) Develop mRNA LNP-loaded microgels as an in vivo...
- This $131,220 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support cancer vaccine research under the Cancer Research Manpower federal grant program (CFDA 93.398). The grant recipient, Stanford University, will develop a new approach to cancer vaccination that directly reprograms cancer cells into antigen presenting cells (APCs) through mRNA-enabled cell reprogramming. Researchers aim to overcome barriers to current vaccination...
- This $414,803 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Massachusetts Institute of Technology (MIT) to develop improved T cell receptor (TCR) engineering strategies for TCR-T cell cancer immunotherapy. The key products and services to be delivered under this grant include: Implementing high-throughput library screens of TCR constant region variants to identify mutations that can improve TCR signaling strength, with...
- This $406,500 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel intratumoral delivery system by Absco Therapeutics, Inc. (Abscotx) to enhance solid tumor immunotherapy. The Oncolymer platform utilizes a thermoresponsive hydrogel and FDA-approved imaging agent to enable sustained, localized delivery of therapeutic agents like immune-sensitizing siRNA and the TLR7 agonist imiquimod. Preclinical studies have...
- This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Pumpkinseed Technologies Inc. for $353,204 supports the development and demonstration of a novel technology called Cell-MAPP. The goal of this Phase I SBIR project is to create the first system capable of continuously monitoring the state transitions of individual T cells in response to antigen exposure. Cell-MAPP will utilize antigen-multimer barcoding and single-cell TCR sequencing to connect...
- This $516,355.74 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, aims to develop new technologies for immunotherapy monitoring and liquid biopsy through the Cancer Research Manpower federal grant program. Specifically, the Massachusetts General Hospital will utilize the funding to create an ultra-high sensitive platform that can map single extracellular vesicles to parent cells at the single particle level and apply it to profile tumor...
- This $306,265 federal Project Grant, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on September 16, 2025, will fund the preclinical development of VAX024 - a novel, second-generation recombinant bacterial minicell-based targeted oncolytic in situ immunization (ISI) agent. VAX024 is designed to overcome limitations of current oncolytic viral therapies by leveraging the grantee's proprietary delivery technology to generate a sterile, user-friendly oncolytic...